MIT researchers have “used an algorithm to sort through millions of genomes to find new, rare types of CRISPR systems that could eventually be adapted into genome-editing tools,” writes Sara Reardon for Nature. “We are just amazed at the diversity of CRISPR systems,” says Prof. Feng Zhang. “Doing this analysis kind of allows us to kill two birds with one stone: both study biology and also potentially find useful things.”
Cognito Therapeutics, founded by Prof. Ed Boyden and Prof. Li Huei Tsai, has developed a “specialized headset that delivers 40Hz auditory and visual stimulation” to the brain, which could potentially slow down the cognitive decline and neurodegeneration in Alzheimer’s disease, reports William A. Haseltine for Forbes. Prof. Li-Huei Tsai “and her team speculated that if gamma wave activity is reduced in Alzheimer’s disease, perhaps, artificially stimulating the brain may enhance synchronized firing and restore cognition,” writes Haseltine.
Institute Prof. Robert Langer speaks with Freakonomics host Stephen Dubner about his approach to failure and perseverance in his professional career. Langer recalls how despite early failures with developing new drug delivery methods, “I really believed that if we could do this, it would make a big difference in science, and I hoped a big difference in medicine.”
Cognito Therapeutics, founded by Prof. Ed Boyden and Prof. Li-Huei Tsai, is using a 40 Hzlight-flickering and auditory headset to help slow the progression of Alzheimer’s and restore cognition, reports William A. Haseltine for Forbes. “A recent pilot clinical trial found that this technology is not only safe and tolerable for home use, but also has a positive impact on reducing symptoms associated with age-related neurodegeneration,” writes Haseltine.
Jasmina Aganovic ’09 founded Future Society, a brand that uses sequenced DNA from extinct flowers to create new scents, reports Celia Shatzman for Forbes. “[With] plants that are from another time, never before have we been able to time travel through smell,” says Aganovic. “But now we can do that, thanks specifically to DNA sequencing. It’s an example of where we're starting off with this concept of limitless nature. It isn't just about stories; it's also about performance.”
Researchers from MIT and elsewhere have “genetically engineered bacteria to efficiently turn plastic waste into useful chemicals,” reports Aristos Georgiou for Newsweek. MIT Prof. James Collins and University of Illinois Urbana-Champaign Prof. Ting Lu explain that they see two potential applications for their work. "In the former case, plastic waste collected from oceans and landfills would be transported to a facility where it would be bioprocessed with engineered microbes,” they note. “In our latter scenario, these microbes could be deployed directly in lands or oceans to bio-transform plastic debris in situ.”
Writing for Nature, graduate student Jelle van der Hilst offers advice on determining whether the data resulting from an experiment is meaningful and useful. “Although in research it is crucial that you don’t fully trust your data until it has been triple-proven and peer-reviewed,” writes van der Hilst, “we do have to gain some operational confidence in our methods and results. Otherwise, crippled by self-doubt, we’d never bring any new research into the world.”
Michal Caspi Tal, a principal research scientist in the department of biological engineering, speaks with Boston Globe reporter Kay Lazar about her research aimed at better understanding why some people develop chronic illness after infection with Lyme disease and Covid-19. “Long Covid and chronic Lyme share so many features that it’s uncanny,” said Tal. “This is a solvable problem. This is not rocket science. This just needs to be looked at with fresh eyes.”
Researchers at MIT and elsewhere have used artificial intelligence to develop a new antibiotic to combat Acinetobacter baumannii, a challenging bacteria known to become resistant to antibiotics, reports Hannah Kuchler for the Financial Times. “It took just an hour and a half — a long lunch — for the AI to serve up a potential new antibiotic, an offering to a world contending with the rise of so-called superbugs: bacteria, viruses, fungi and parasites that have mutated and no longer respond to the drugs we have available,” writes Kuchler.
Prof. Regina Barzilay speaks with Nicole Estephan of WCVB-TV’s Chronicle about her work developing new AI systems that could be used to help diagnose breast and lung cancer before the cancers are detectable to the human eye.
MIT researchers have discovered an RNA-guided DNA-cutting enzyme in eukaryotes, reports Science. “The researchers speculate that eukaryotic cells may have gained the newly identified editing genes from transposable elements—so-called jumping genes—they received from bacteria,” writes Science.
MIT researchers have identified a new biological editing system that could “potentially be even more precise than CRISPR gene editing,” reports Laura Baisas for Popular Science. The new system, based on a protein called Fanzor, is “the first programmable RNA-guided system discovered in eukaryotes,” Baisas notes.
Researchers from MIT and McMaster University have used artificial intelligence to identify a new antibiotic that can fight against a drug-resistant bacteria commonly found in hospitals and medical offices, reports Ken Alltucker for USA Today. The researchers believe the AI “process used to winnow thousands of potential drugs to identify one that may work is an approach that can work in drug discovery,” writes Alltucker.
Researchers from MIT and elsewhere have used artificial intelligence to develop a new antibiotic to address Acinetobacter baumannii, a bacteria known for infecting wounds, lungs and kidneys, reports Harland-Dunaway for The World.
Using a machine-learning algorithm, researchers from MIT and McMaster University have discovered a new type of antibiotic that works against a type of drug-resistant bacteria, reports Brenda Goodman for CNN. Goodman notes that the compound “worked in a way that stymied only the problem pathogen. It didn’t seem to kill the many other species of beneficial bacteria that live in the gut or on the skin, making it a rare narrowly targeted agent.”